METACARE Completes 6 Billion KRW Third-Party Allotment Capital Increase to Largest Shareholder Metaraps... 28% Share Dilution Raises Shareholder Value Concerns
METACARE completed a 6 billion KRW third-party allotment capital increase to its largest shareholder Metaraps.
The proceeds are intended for operating funds and acquisition of other company securities, but specific uses remain unclear.
The issuance increases total outstanding shares by 28% significantly diluting existing shareholders, and the issue price of 1,230 KRW represents a 17% discount to the current share price.
Allocating new shares solely to the largest shareholder raises governance concerns, and although the new shares are under a one-year lock-up, short-term downward pressure on the stock price is expected.
[AI Summary]METACARE executed an aggressive capital raise resulting in 28% share dilution through a related-party allotment. With ambiguous fund usage and a discounted issue price, existing shareholder value is impaired, likely exerting negative pressure on the stock price in the near term.
KOSPI Filing Information
Result of Issuance of Rights Offering or Equity-Related Bonds (Voluntary Disclosure)